Cohort demographic and clinical characteristics at first HER2-targeted therapy dispensing
| Metastatic | Early-stage | ||
|---|---|---|---|
| Trastuzumab | Lapatinib | trastuzumab | |
| Patients with at least one dispensing (n) | 5631 | 1099 | 11 406 |
| Age, median (IQR) | 56 (48–65) | 56 (48–63) | 54 (47–63) |
| Weight in kilograms at first dispensing, median (IQR) | 70 (60–80) | 70 (60–81) | – |
| HER2-positive by IHC 3+, n (%) | 3542 (62.9) | 585 (53.2) | |
| HER2-positive by ISH, n (%) | 2193 (38.9) | 496 (45.1) | |
| Fact of death, n (%) | 3777 (67.1) | 892 (81.2) | 898 (7.9) |
| Hormone receptor positive, n (%)* | 3113 (55.3) | 617 (56.1) | 6439 (56.4) |
| Comorbidities†, n (%) | |||
| 0–2 | 492 (8.7) | 44 (4.0) | 1928 (16.9) |
| 3–4 | 921 (16.4) | 149 (13.6) | 3054 (26.8) |
| 5–6 | 1137 (20.2) | 244 (22.2) | 2689 (23.6) |
| 7+ | 3081 (54.7) | 662 (60.2) | 3735 (32.7) |
*Dispensing of a hormonal agent indicated hormone receptor positivity.
†Comorbidities assessed from dispensing claims using the RxRisk algorithm.
IHC, immunohistochemistry; ISH, in situ hybridisation; HER2, human epidermal growth factor receptor 2.